Review

The Challenges of Melanoma during COVID-19 Pandemic

Raluca-Gabriela MIULESCU1, Mihai Cristian DUMITRASCU2,3, Carmen Cristina DRAGHICI1, Diana SPINU1, Adelina POPA1, Octavian ANDRONIC2,4, Dan Nicolae PADURARU2,4, Dumitru FERECHIDE5, Florica SANDRU1,2

Department of Dermatology, “Elias” Emergency University Hospital, Bucharest, Romania
2,3 Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3 Department of Obstetrics & Gynecology, „Elias” Emergency University Hospital, Bucharest, Romania
4 IIIrd Department of General Surgery, Emergency University Hospital, Bucharest, Romania
5 IInd Department of Physiology “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

Corresponding author: Mihai Cristian DUMITRASCU, 169 Splaiul Independentei, Bucharest, Romania.
E-mail: drdumitrascu@yahoo.com

Abstract

Diagnosis, treatment and follow-up of patients with melanoma during COVID-19 pandemic is quite challenging. These patients are often immunocompromised, but, on the other hand, management of this malignant skin cancer should not be delayed. It is necessary to diagnose and stage the melanoma as soon as possible, in an attempt to provide a better prognosis. There are few data regarding the treatment of melanoma during COVID-19 pandemic. However, the general recommendations suggest testing all cancer patients prior administration of the therapy. The European Society for Medical Oncology (ESMO) provided guidelines regarding therapy of this skin cancer during COVID-19 pandemic. Every patient is different, and it is always important to evaluate the risks and benefits.

Keywords: melanoma, COVID-19 pandemic, immunotherapy, target therapy, ESMO guidelines.

Rezumat

Diagnosticul, tratamentul și urmărirea pacienților cu melanom în timpul pandemiei COVID-19 este destul de dificilă. Acești pacienți sunt adesea imunodeprimăți, dar, pe de altă parte, tratamentul acestui cancer de piele nu trebuie întârziat. Este necesar să diagnosticăm și să tratăm melanomul cât mai curând posibil, în încercarea de a oferi un prognostic mai bun. Există puține date referitoare la tratamentul melanomului în timpul pandemiei COVID-19. Cu toate acestea, recomandările generale sugerează testarea tuturor pacienților cu cancer înainte de administrarea terapiei. Societatea Europeană pentru Oncologie Medicală (ESMO) a furnizat ghiduri privind terapia acestui cancer de piele în timpul pandemiei COVID-19. Fiecare pacient este diferit și este întotdeauna important să evaluezi riscurile și beneficiile.

Cuvinte cheie: melanom, pandemie COVID-19, imunoterapie, terapie țintită, ghiduri ESMO.
INTRODUCTION

In December 2019, several cases of pneumonia of unknown origin were diagnosed in Wuhan, China. Shortly, the scientists discovered a new type of coronavirus. They named it severe acute respiratory syndrome-coronavirus 2, or SARS-CoV-2.

On March 2020, the WHO (World Health Organisation) declared COVID-19 infection pandemic, and indicated three priorities for all countries: protection of people at highest risk of severe disease, as patients with comorbidities (for example, cancers), protection of health workers, and supporting all the vulnerable countries in containing infection.

Pandemia with this new coronavirus has a defining impact on medical care. Regarding patients with dermatological conditions, one of the most affected group of patients by this pandemic, are the ones with melanoma, because they are immunocompromised hosts, and are more likely to develop severe forms of infection. On the other hand, melanoma is a serious skin cancer, whose diagnosis and treatment cannot be postponed.

MANAGEMENT OF MELANOMA AND COVID-19

Melanoma is an aggressive form of skin cancer, with a high mortality. It seems that melanoma is caused by the several genetic in mutations (located in the skin, eye, inner ear and leptomeninges).

As for the epidemiology of melanoma, it affects most frequently caucasians patients, equally males and females. It is important to diagnose this skin cancer early. Metastasis melanoma has often a poor prognosis. This is the reason why staging of melanoma is so important.

Today, the diagnosis of melanoma is based on the staging manual of the American Joint Committee on Cancer, implemented in 2018. Multiple changes have been made to the previous guide: minimal changes in measurements of tumor thickness, removal of mitotic activity, expansion of the regional lymph node (N) categories based on number of positive regional lymph nodes, expansion of metastasis (M) categories based on location of metastasis, and expanded stage groupings in stage III disease to better stratify long term prognosis.

Further more, staging correctly the melanoma, provides the best therapy for the patient.

As mentioned previously, it is vital for the patient with melanoma to perform a skin biopsy with histopathological examination, even during pandemia with COVID-19. Diagnosis of this tumor is established by excisional biopsy. The safety margin, of initial biopsy, is 1-3 mm, around the lesion, and a cuff of subcutaneous fat deep of the tumor. Also, an incisional, partial biopsy may be performed instead of complete biopsy. This last method should be avoided as it may inaccurately stage the melanoma, or even negatively affect treatment planning.

Although an excisional biopsy was performed, we should complete removal of the lesion, with a wider and deeper excision, as soon as we get the initial histopathological report of the biopsy. In this case, the histopathological examination is also essential as it must confirm clear margins. The most commonly, a margin of 0.5 cm is adequate: rare, these patients experience recurrence. So, in this situation, we have another example why we cannot delay the complete removal of melanoma.

When it comes to these patients, an important aspect should also refer to the right time to perform sentinel lymph node biopsy. When recommended, it is necessary to be performed before wide excision of the primary melanoma, or in the same operative setting. The purpose is to minimize disruption of the lymphatic channels and optimize the accuracy of lymphatic mapping, as well as identification of the correct sentinel lymph nodule. Thus, this intervention can be delayed, as there is no evidence that influences survival.

Any of the patients mentioned before should be tested for COVID-19 if they develop fever, or lower respiratory symptoms, such as dyspnea, hypoxia or cough. However, patients with melanoma should also be tested for other causes of respiratory symptoms: influenza, bacterial pneumonia or others disorders that may mimic symptoms of COVID-19.

Adjuvant therapies are indicated to improve survival: targeted therapies or immunotherapy.

Some authors suggest that 70% of patients with melanoma suffer from mutations in genes of key signaling pathways. It seems that mutations produce cell proliferation and malignant phenotype. In fact, these therapies (small molecule inhibitors or antibodies) are directed against mutated proteins. Because, often, in case of melanoma we challenge with mechanisms of resistance to therapy, a synergy between strategies (immunotherapy, targeted therapy, chemotherapy) which target multiple pathways, would be the correct management. Some of the options for these patients are: Nivolumab, Ipilimumab, Vemurafenib+Cobimetinib, Dabrafenib+Trametinib.
During pandemic, the question we should ask is if is indicated to test these patients, treated with immunosuppressive agents. Some authors support the idea that all cancer patients should routinely be tested, 48 to 72 hours prior to administration of the therapy, even if they are asymptomatic or have no knowledge of exposure to COVID-19.22

Unfortunately, there are few data regarding treatment of melanoma in case of COVID-19 positive patients. Some guidelines recommend not to discontinue undergoing therapy. However, there is no evidence on how to manage an asymptomatic patient, or a symptomatic one who follows immunotherapy or target therapy.23

**ESMO GUIDELINES**

Informations provided by The European Society for Medical Oncology (ESMO) indicate, for patients who follow chemotherapy, radiotherapy or immunotherapy, to be swabbed for COVID-19, before every treatment session. Furthermore, initiation or continuation of therapy should be discussed for each patient separately, whether it is positive, paucisymptomatic or asymptomatic.24

To synthesize, we will highlight the most important aspects related to melanoma management during the COVID-19 pandemic, specified by ESMO. Thus, our high priority patients would be the ones new diagnosed with invasive primary melanoma, except the skin cancer is incipient (Tis or T1a, and we already performed a wide excision). Also at high risk are post-operative patients, who develop complications. ESMO defines high/medium priority, the patients who accuse new symptoms from treatment, and recommends us trying to manage them by telemedicine, if possible. In case of melanoma survivors, or patients who should have there follow-up only, because they do not have active treatment, maybe the telemedicine would also be a good idea. These patients, together with the ones with dysplastic nevi, represent a low priority.25

When it comes to surgery in primary melanoma, there are 3 categories at high priority: curative resection for stage III, surgical management of complications or patients in neoadjuvant studies who had previously planned surgery.25

As for high or medium priority, should be mentioned: patients with invasive primary melanoma T1b/higher should benefit from wide excision and sentinel lymph (but, as specified previously, this can be delayed); we should perform wide excision for T1a or lower; As well as resection of oligo-metastatic disease.25

ESMO experts consider at high priority, patients who receive adjuvant systemic therapies for stage III melanoma: they should continue therapy if they are part of a clinical trial, providing patient benefits outweigh risks. High or medium priority is represented by patients who follow adjuvant targeted or immunotherapies, with stage III melanoma.25

Other recommendations of ESMO refer to advanced melanoma, non-operable stage III or IV. For these patients, systemic therapies should be administrated as follows: immunotherapies or targeted therapies for non-operable stage III/IV; patients who are part of a clinical trial should continue the treatment, or course, providing the patient benefits outweigh risks.25

Experts also define priorities for radiotherapy for non-operable stage III/IV melanoma. With high priority, are patients with brain metastases, who have indication for stereotactic radiosurgery, threatening lesion or acute spinal cord compression. As for symptomatic metastases, irradiation is considered a high/medium priority. Low priority includes: adjuvant radiotherapy post radical lymphadenectomy and irradiation of asymptomatic, not threatening metastases.25

**CONCLUSION**

In conclusion, management of melanoma during COVID-19 pandemic is challenging. In most cases, therapy should not be delayed, as progression of the tumor is associated with worse prognosis. However, every case should be discussed separately, and the best decisions should be taken, always balancing the risks with the benefits.

**Compliance with ethics requirements:** The authors declare no conflict of interest regarding this article. The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from all the patients included in the study.
References

1. World Health Organization Novel coronavirus – China. 2020. https://www.who.int/csr/don/12-january-2020-novel-corona-virus-china/en/
2. World Health Organization Director-General’s opening remarks at the media briefing on COVID-19 – 24 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---24-february-2020 (Accessed on February 26, 2020).
3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol 2020.
4. Brancaccio G, Russo T, Lailas A, Moscarella E, A gozzino M, Argenziano G. Melanoma: clinical and dermoscopic diagnosis. G Ital Dermatol Venereol. 2017 Jun;152(3):213-223. doi: 10.23736/S0392-0488.17.05571-7. Epub 2017 Jan 24.
5. Beatriz Domingues, José Manuel Lopes, Paula Soares, Helena Pópolo. Melanoma treatment in review. Immunotargets Ther. 2018; 7: 35–49. Published online 2018 Jun 7. doi: 10.2147/ITT.S134842
6. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445(7130):851–857. [PubMed] [CrossRef]
7. Jiang BP, Zhang L, Guo XL, et al. Poly(N-phenylglycine)-based nanoparticles as highly effective and targeted near-infrared photothermal therapy/photodynamic therapeutic agents for malignant melanoma. Small. 2017;13(8):1–15. [PubMed] [Google Scholar]
8. Gerami P, Busam K, Cochran A, Cook MG, Duncan LM, Elder DE, Fullen DR, Guitart J, Leboit PE, Mihm MC, et al. Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathology. 38(7):934–940. doi:10.1097/PAS.0000000000000198. [PubMed] [CrossRef] [Google Scholar]
9. Lauren E, Davis, Sara C, Shalin, Alan J. Tackett. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11): 1366–1379. Published online 2019 Aug 1. doi: 10.1080/15384047.2019.1640032
10. Swanson NA, Lee KK, Gorman A, Lee HN. Biopsy techniques: diagnosis of melanoma. Dermatol Clin. 2002;20:677–80. [PubMed] [Google Scholar]
11. Lees VC, Briggs CJ. Effect of initial biopsy procedure on prognosis in stage 1 invasive cutaneous malignant melanoma: review of 1086 patients. Br J Surg. 1991;78:1108–10. [PubMed] [Google Scholar]
12. S Tadiparthi, S Panchani, A Iqbal. Biopsy for Malignant Melanoma — Are We Following the Guidelines? Ann R Coll Surg Engl. 2008 May; 90(4): 322–325. doi: 10.1080/003588408X285856
13. Swetter SM, Tsao B, Bichakjian CK. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019 Jan;80(1):208-250. doi: 10.1016/j.jaad.2018.08.055. Epub 2018 Nov 1.
14. Christopher J. Gannon, Dennis L. Rousseau Jr., Merrick I. Ross. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. ACS Journals. First published:24 October 2006. https://doi.org/10.1002/cncr.22320
15. Oude Gphuis CM, Verhoef C, Rutkowski P, et al. The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. Eur J Surg Oncol 2016; 42(12):1906-1913.
16. Robert G Uzzo, Alexander Kutikov, Daniel M Geynisman, Coronavirus disease 2019 (COVID-19): Cancer care during the pandemic. UpToDate May 08, 2020.
17. van Zeijl M, van den Eertwegh A, Haanen J, Wouters M. (Neo)adjuvant systemic therapy for melanoma. Eur J Surg Oncol. 2017;43(3):534–543. [PubMed] [Google Scholar]
18. Batus M, Waheed S, Ruby C, Petersen L, Bines SD, Kaufman HL. Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol. 2013;14(3):179–194. [PMC free article] [PubMed] [Google Scholar]
19. Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol. 2011;223(2):242–251. [PubMed] [Google Scholar]
20. Beatriz Domingues, José Manuel Lopes, Paula Soares, Helena Pópolo. Melanoma treatment in review. Immunotargets Ther. 2018; 7: 35–49. Published online 2018 Jun 7. doi: 10.2147/ITT.S134842
21. Iwona Lugowska, Paweł Tetycz, Piotr Rutkowski. Immunotherapy of melanoma. Contemp Oncol (Pozn). 2018 Mar; 22(1A): 61–67. Published online 2018 Mar 5. doi: 10.5114/wco.2018.73889
22. https://www.idsociety.org/practice-guideline/covid-19-guide-line-diagnostics/ (Accessed on May 08, 2020).
23. Conforti C, Giuffrida R, Di Meo N, Zalaudek. Management of advanced melanoma in the COVID-19 era. Dermatol Ther. 2020 Apr 22.e12453. doi: 10.1111/dth.13444.
24. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic
25. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/melanoma-in-the-covid-19-era.